1.18
+0(+0.00%)
Currency In USD
Address
245 First Street
Cambridge, MA 02142
United States of America
Phone
617 871 2098
Website
Sector
Healthcare
Industry
Biotechnology
Employees
181
First IPO Date
March 20, 2014
| Name | Title | Pay | Year Born |
| John Butler | CEO, President & Director | 1.93M | 1964 |
| Erik John Ostrowski | Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer | 412,812 | 1972 |
| Nicholas Grund | Senior VP & Chief Commercial Officer | 684,224 | 1970 |
| Steven Keith Burke | Senior VP and Chief Research & Development Officer | 1.03M | 1961 |
| Mercedes Carrasco | Senior Director of Investor & Corporate Communications | 0 | N/A |
| Richard C. Malabre | Chief Accounting Officer | 0 | 1961 |
| Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary | 0 | N/A |
| Kimberly Garko | Senior VP & Chief Technical Officer | 0 | N/A |
| Meredith Bowman | Senior VP & Chief People Officer | 0 | N/A |
| Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration | 0 | N/A |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.